Biobeat Raises $50 Million Series B to Expand Cuff-less Blood Pressure Monitor

Biobeat Technologies has raised $50 million in Series B equity financing to advance commercialization of its FDA-cleared, cuff-less 24-hour ambulatory blood pressure monitoring system, announced in a press release. The funding round was led by new investors Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, with participation from a strategic investor.

The proceeds will be used to expand Biobeat’s U.S. commercial operations. The company’s patch-worn device enables continuous ambulatory blood pressure monitoring without the need for a traditional cuff, allowing patients to maintain normal daily activities and sleep undisturbed. After monitoring, the disposable patch automatically generates a report integrated into the institution’s electronic medical records.

The financing also brings new members to Biobeat’s board of directors, including representatives from Ally Bridge, OrbiMed, and Elevage. The company operates from Tel Aviv, Israel, and Boca Raton, Florida, and aims to make 24-hour ambulatory blood pressure monitoring a standard of care for hypertension management.